Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 101–200 of 1,001
STAT3 and apoptosis challenges in cancer
Fathi, N., Rashidi, G., Khodadadi, A., Shahi, S., & Sharifi, S. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.121 · Cited by 187
PROTACs to address the challenges facing small molecule inhibitors
Martín-Acosta, P., & Xiao, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 172
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.4 · Cited by 185
Liu, X., Huang, J., Chen, T., Wang, Y., Xin, S., Li, J., Pei, G., & Kang, J. (2008) · Cell Research · doi:10.1038/cr.2008.309 · Cited by 181
RAS-mediated oncogenic signaling pathways in human malignancies
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
“The Signal Transducer and Activator of Transcription (STAT) family of proteins are cytoplasmic transcription factors with important roles in the responses to cytokines and growth factors, including promoting cell growth and differentiation, and inflammation and immune responses [1, 2].”
BackgroundLi, F., Rajendran, P., & Sethi, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00874.x · Cited by 176
“Among the STATs, STAT3 is perhaps the most closely linked to tumourigenesis, is often constitutively activated in many human cancer cells and plays an active role at all levels of tumourigenesis (Ihle, 1996; Darnell, 2002).”
Antitumorigenic potential of STAT3 alternative splicing modulation
Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108482108 · Cited by 176
“Its activation is due to transient phosphorylation of cytoplasmic monomers that dimerize, translocate to the nucleus, and bind to specific promoter sequences, thereby regulating gene expression (1).”
BackgroundRen, D., Lin, B., Zhang, X., Peng, Y., Ye, Z., Ma, Y., Liang, Y., Cao, L., Li, X., Li, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17971 · Cited by 172
“The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway was first identified as a mediator of cytokine signaling in a study of interferon signaling and primarily consisted of three main components: a cell surface receptor JAK and two STAT proteins [8].”
BackgroundAn integrative ENCODE resource for cancer genomics
Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson, W., Clarke, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14743-w · Cited by 172
Desmet, C. J., Gallenne, T., Prieur, A., Reyal, F., Visser, N. L., Wittner, B. S., Smit, M. A., Geiger, T. R., Laoukili, J., Iskit, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222085110 · Cited by 172
“Because transcription factors are key integrators of signaling pathways that connect biological characteristics to clinical outcome (12), we focused our attention on this class of proteins.”
BackgroundMethodKlampfer, L. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056491 · Cited by 171
Gào, X., & Schöttker, B. (2017) · Oncotarget · doi:10.18632/oncotarget.17128 · Cited by 147
“Some hyperactivated transcription factors in cancer cells have been linked with chemotherapy and radiotherapy resistance up to treatment failure [99].”
BackgroundStructural Biology of STAT3 and Its Implications for Anticancer Therapies Development
Sgrignani, J., Garofalo, M., Matkovic, M., Merulla, J., Catapano, C. V., & Cavalli, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061591 · Cited by 165
“, DNA binding proteins controlling the rate of gene transcription; TFs) are nodal points in signaling pathways and among the most frequently affected genes in cancer [1,2].”
BackgroundConsistent Feature Selection for Pattern Recognition in Polynomial Time
Nilsson, R., Peña, J. M., Björkegren, J., & Tegner, J. N. (2007) · Journal of Machine Learning Research · doi:10.5555/1248659.1248680 · Cited by 216
Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer
Stolzenburg, S., Rots, M. G., Beltran, A. S., Rivenbark, A. G., Yuan, X., Qian, H., Strahl, B. D., & Blancafort, P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks360 · Cited by 165
“Aberrant regulation of TF expression is frequently found in human malignancies and associated with specific tumor subtypes (1).”
Chen, J., Wang, J., Lin, L., He, L., Wu, Y., Zhang, L., Yi, Z., Chen, Y., Pang, X., & Liu, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0648 · Cited by 164
“Constitutively active STAT3 has been implicated in the induction of resistance to apoptosis, possibly through the expression of Bcl-2, Bcl-xL, and cyclin D1 (46).”
BackgroundMertens, C., Zhong, M., Krishnaraj, R., Zou, W., Chen, X., & Darnell, J. E. (2006) · Genes & Development · doi:10.1101/gad.1485406 · Cited by 164
PRL3 Promotes Cell Invasion and Proliferation by Down-regulation of Csk Leading to Src Activation
Liang, F., Liang, J., Wang, W.-Q., Sun, J.-P., Udho, E., & Zhang, Z.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608940200 · Cited by 162
Kowshik, J., Baba, A. B., Giri, H., Deepak Reddy, G., Dixit, M., & Nagini, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109114 · Cited by 158
“STAT-3 is found to be constitutively active in different carcinomas and inhibition of STAT-3 activation correlates with suppression of malignant cells both in vitro and in vivo [36,37].”
BackgroundSweeney, C. J., Mehrotra, S., Sadaria, M. R., Kumar, S., Shortle, N. H., Roman, Y., Sheridan, C., Campbell, R. A., Murry, D. J., Badve, S., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0030 · Cited by 158
“The transcription factors nuclear factor nB (NF-nB), activator protein 1, and signal transducers and activators of transcription 3 are the major transcription factors that control the expression of antiapoptotic and proapoptotic genes that determine the sensitivity of cancer cells to therapy (2, 4, 5).”
BackgroundTargeting STAT3 signaling pathway in cancer by agents derived from Mother Nature
Mohan, C. D., Rangappa, S., Preetham, H. D., Chandra Nayaka, S., Gupta, V. K., Basappa, S., Sethi, G., & Rangappa, K. S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.016 · Cited by 157
Bartling, B. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh333 · Cited by 157
Anticancer Effects of Niclosamide in Human Glioblastoma
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2895 · Cited by 156
Cancer chemoprevention: scientific promise, clinical uncertainty
Sporn, M. B., & Liby, K. T. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0319 · Cited by 176
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 160
“As a nuclear transcription factor lacking its own enzymatic activity, STAT3 is a challenging target for both antibody and smallmolecule drugs (8, 17, 18).”
BackgroundMolecular Regulation of Human Cathepsin B: Implication in Pathologies
Yan, S., & Sloane, B. F. (2003) · Biological Chemistry · doi:10.1515/bc.2003.095 · Cited by 153
Novel Mode of Action of Tylophorine Analogs as Antitumor Compounds
Gao, W., Lam, W., Zhong, S., Kaczmarek, C. G., Baker, D. C., & Cheng, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1904 · Cited by 153
“We focused on the activator protein-1, the CRE, and the NF- B signaling pathways, because these pathways have been well studied and are important players in the control of cell growth, differentiation, and survival (39, 40).”
BackgroundTurkson, J., Zhang, S., Mora, L. B., Burns, A., Sebti, S., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 151
The Role of STAT-3 in the Induction of Apoptosis in Pancreatic Cancer Cells by Benzyl Isothiocyanate
Sahu, R. P., & Srivastava, S. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn470 · Cited by 156
Resnick, M. A., & Inga, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633803100 · Cited by 149
Targeting Transcription Factors for Cancer Gene Therapy
Libermann, T. A., & Zerbini, L. F. (2006) · Current Gene Therapy · doi:10.2174/156652306775515501 · Cited by 170
Laissue, P. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0938-x · Cited by 149
Thornton, S., Anand, N., Purcell, D., & Lee, J. W. J. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0461-8 · Cited by 166
Biology and Clinical Relevance of the Micropthalmia Family of Transcription Factors in Human Cancer
Haq, R., & Fisher, D. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6223 · Cited by 146
“Over the ensuing years, many other dysregulated transcription factors have been implicated in human cancers, including breast, colon, lung, and hematopoietic cancers.(3) Recent research has implicated a family of transcription factors known as the micropthalmia (MiT) -related transcription factors in melanoma, sarcoma…”
BackgroundComplementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer
Roti, G., Carlton, A. L., Ross, K. N., Markstein, M., Pajcini, K. V., Su, A. H., Perrimon, N., Pear, W. S., Kung, A. L., Blacklow, S. C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.015 · Cited by 149
Discovery of Chromone‐Based Inhibitors of the Transcription Factor STAT5
Müller, J., Sperl, B., Reindl, W., Kiessling, A., & Berg, T. (2008) · ChemBioChem · doi:10.1002/cbic.200700701 · Cited by 145
A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population
Qu, Y., Feng, J., Wu, X., Bai, L., Xu, W., Zhu, L., Liu, Y., Xu, F., Zhang, X., Yang, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29577-x · Cited by 164
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
Fra-1 a target for cancer prevention or intervention
Young, M. R., & Colburn, N. H. (2006) · Gene · doi:10.1016/j.gene.2006.05.001 · Cited by 159
Natural Withanolides in the Treatment of Chronic Diseases
White, P. T., Subramanian, C., Motiwala, H. F., & Cohen, M. S. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-41334-1_14 · Cited by 139
“Activation of STAT proteins depends on their binding to cytokines and growth factor receptors on the plasma membrane followed by tyrosine phosphorylation either directly by receptor tyrosine kinases (RTKs) or by non RTKs such as JAK or Src [106, 107] .”
BackgroundPromoter‐specific transcriptional interference and c‐myc gene silencing by siRNAs in human cells
Napoli, S., Pastori, C., Magistri, M., Carbone, G. M., & Catapano, C. V. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.139 · Cited by 137
Lee, J. H., Chiang, S. Y., Nam, D., Chung, W., Lee, J., Na, Y.-S., Sethi, G., & Ahn, K. S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.008 · Cited by 144
Transcription Factor Drug Targets
Papavassiliou, K. A., & Papavassiliou, A. G. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25605 · Cited by 145
FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair
Park, Y.-Y., Jung, S. Y., Jennings, N. B., Rodriguez-Aguayo, C., Peng, G., Lee, S.-R., Kim, S. B., Kim, K., Leem, S.-H., Lin, S.-Y., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs167 · Cited by 135
“TFs function as oncogenes or tumor suppressors in diverse human cancers (2,3).”
InfluentialEiring, A. M., Page, B. D. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A. J., et al. (2015) · Leukemia · doi:10.1038/leu.2014.245 · Cited by 131
Objective assessment of cancer genes for drug discovery
Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 149
“%) supports their importance in cancer 30,31 , as exemplified by nuclear factor-κB (NF-κB) 32 , signal transducers and activators of transcription (STATs) 33 and the transcription factor ETS 34 , but also reveals the tension between their importance in the molecular pathology of cancer versus their…”
BackgroundThe MYC Oncogene as a Cancer Drug Target
Hermeking, H. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481949 · Cited by 132
Fishman, P. (1992) · international Journal of Oncology · doi:10.3892/ijo_00000008 · Cited by 132
Analysis of Time-Series Gene Expression Data: Methods, Challenges, and Opportunities
Androulakis, I. P., Yang, E., & Almon, R. R. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.151904 · Cited by 142
STAT3 inhibitors for cancer therapy: Have all roads been explored?
Fagard, R., Metelev, V., Souissi, I., & Baran-Marszak, F. (2013) · JAK-STAT · doi:10.4161/jkst.22882 · Cited by 129
The Jun/miR-22/HuR regulatory axis contributes to tumourigenesis in colorectal cancer
Liu, Y., Chen, X., Cheng, R., Yang, F., Yu, M., Wang, C., Cui, S., Hong, Y., Liang, H., Liu, M., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-017-0751-3 · Cited by 136
“Transcription factors (TFs) are often dysregulated in cancers and closely associated with cancer progression [45, 46] and cancer-related miRNA expression [47].”
Nagel‐Wolfrum, K., Buerger, C., Wittig, I., Butz, K., Hoppe‐Seyler, F., & Groner, B. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.170.2.3 · Cited by 146
“Although their activated forms are found in tumor cells and some of their functional roles in the transformation process have been shown, it has proven difficult to exploit them as targets for therapeutic intervention (5).”
BackgroundLou, Z., O'Reilly, S., Liang, H., Maher, V. M., Sleight, S. D., & McCormick, J. J. (2005) · Cancer Research · doi:10.1158/0008-5472.1007.65.3 · Cited by 128
“Other transcription factors known to act as oncoproteins when up-regulated include c-JUN, and STATS (66).”
BackgroundFofaria, N. M., & Srivastava, S. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu233 · Cited by 132
RetractedJenkins, G. J. S. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh032 · Cited by 128
“Furthermore, NF-κB activation has been shown to be correlated with chemoresistance [35,36], indeed inhibition of NF-κB improves tumour shrinkage by chemotherapy [22,37] which may be an effective avenue for cancer therapy [38].”
BackgroundLipogenesis in cancer progression (Review)
Mounier, C., Bouraoui, L., & Rassart, É. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2441 · Cited by 139
“One of the first events of EMT is the loss of E-cadherin, a transmembrane protein implicated in formation of the tight junctions (33).”
BackgroundInfluentialMandal, P. K., Gao, F., Lu, Z., Ren, Z., Ramesh, R., Birtwistle, J. S., Kaluarachchi, K. K., Chen, X., Bast, R. C., Liao, W. S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000882 · Cited by 127
Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition
Chang, H., Liu, Y., Xue, M., Liu, H., Du, S., Zhang, L., & Wang, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw126 · Cited by 127
“Aberrant reactivation of lineage specific TFs is a well-known phenomena during tumorigenesis (44,45).”
BackgroundColeman, Ren, Z., Mandal, P. K., Cameron, A. G., Dyer, G. A., Muranjan, S., Campbell, M., Chen, X., & McMurray, J. S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050513m · Cited by 127
Maguire, O., Collins, C., O'Loughlin, K., Miecznikowski, J., & Minderman, H. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21068 · Cited by 124
Shishodia, S., & Aggarwal, B. B. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_8 · Cited by 126
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003082 · Cited by 122
Ren, X., Yang, X., Cheng, B., Chen, X., Zhang, T., He, Q., Li, B., Li, Y., Tang, X.-R., Wen, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms14053 · Cited by 124
“In contrast to the numerous signalling pathway genes, a limited list of dysregulated TFs in multiple cancers has been suggested as appropriate targets for the development of anticancer drugs 11 .”
Transcription Factor Inhibition: Lessons Learned and Emerging Targets
Chen, A. W., & Koehler, A. N. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.004 · Cited by 131
Kumar, D., Gokhale, P. C., Broustas, C. G., Chakravarty, D., Ahmad, I., & Kasid, U. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207123 · Cited by 126
“Constitutive upregulation of NF-kB has been reported in a variety of cancers (Bargou et al., 1997; Nakshatri et al., 1997; Sovak et al., 1997; Mori et al., 1999; Wang et al., 1999b; Darnell, 2002; Orlowski and Baldwin, 2002; Scaife et al., 2002; Nair et al., 2003).”
BackgroundHenke, E., Perk, J., Vider, J., de Candia, P., Chin, Y., Solit, D. B., Ponomarev, V., Cartegni, L., Manova, K., Rosen, N. X., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1366 · Cited by 122
Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma
Li, S., Priceman, S. J., Xin, H., Zhang, W., Deng, J., Liu, Y., Huang, J., Zhu, W., Chen, M., Hu, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081657 · Cited by 120
“STAT3 is persistently activated by non-receptor tyrosine kinases such as Janus kinases (JAKs) or Src family kinases [13,19,26,27,28], which induce its dimerization and nuclear translocation required for its transcriptional regulation [13,19,29].”
NF-κB Regulates Expression of the MHC Class I-Related Chain A Gene in Activated T Lymphocytes
Molinero, L. L., Fuertes, M. B., Girart, M. V., Fainboim, L., Rabinovich, G. A., Costas, M. A., & Zwirner, N. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5583 · Cited by 116
“cycle (48) and cancer development (27, 49, 50).”
BackgroundThe antitumor activity of naturally occurring chromones: A review
Duan, Y.-D., Jiang, Y., Guo, F.-X., Chen, L., Xu, L., Zhang, W., & Liu, B. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.04.012 · Cited by 117
Lerner, L., Henriksen, M. A., Zhang, X., & Darnell, J. E. (2003) · Genes & Development · doi:10.1101/gad.1135003 · Cited by 114
“This gene was chosen because it is activated by IL-6 through action of STAT3 and because STAT3 has gained attention as a persistently active and necessary factor for human cancer cells to avoid apoptosis (Darnell 2002).”
BackgroundInfluentialProgress towards the development of SH2 domain inhibitors
Kraskouskaya, D., Duodu, E., Arpin, C. C., & Gunning, P. T. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35449k · Cited by 114
FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma
Ramsey, M. R., Wilson, C., Ory, B., Rothenberg, S. M., Faquin, W. C., Mills, A. A., & Ellisen, L. W. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68899 · Cited by 123
“One underexplored area for potential therapeutic intervention in SCC and other cancers involves deregulation of various lineagespecific transcription factors (6).”
BackgroundTargeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy
Rajagopal, C., Lankadasari, M. B., Aranjani, J. M., & Harikumar, K. B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.034 · Cited by 117
Patrick, A. N., Cabrera, J. H., Smith, A. L., Chen, X. S., Ford, H. L., & Zhao, R. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2505 · Cited by 130
Ma, F., Yang, Y. P., & Zhang, C. (2014) · Analytical Chemistry · doi:10.1021/ac5017369 · Cited by 113
Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer
Hong, Y., Liang, H., Ur-Rehman, U., Wang, Y., Zhang, W., Zhou, Y., Chen, S., Yu, M., Cui, S., Liu, M., et al. (2016) · Scientific Reports · doi:10.1038/srep37421 · Cited by 120
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Martínez‐Sáez, O., Borau, P. G., Alonso‐Gordoa, T., Molina‐Cerrillo, J., & Grande, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.013 · Cited by 116
Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model
Jung, Y. Y., Shanmugam, M. K., Narula, A. S., Kim, C., Lee, J. H., Namjoshi, O. A., Blough, B. E., Sethi, G., & Ahn, K. S. (2019) · Cancers · doi:10.3390/cancers11010049 · Cited by 110
Wong, G. L., Manore, S. G., Doheny, D. L., & Lo, H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.003 · Cited by 118
The SIX1-EYA transcriptional complex as a therapeutic target in cancer
Blevins, M. A., Towers, C. G., Patrick, A. N., Zhao, R., & Ford, H. L. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.978860 · Cited by 117
“Aberrant transcription factor expression can result in altered gene expression profiles and is known to be fundamental to the acquisition of hallmark capabilities [112].”
BackgroundHedgehog–Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer
Altaba, A. R. I., Stecca, B., & Sánchez, P. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00451-8 · Cited by 120
Pandey, M. K., Sung, B., & Aggarwal, B. B. (2009) · International Journal of Cancer · doi:10.1002/ijc.25059 · Cited by 108
“Signal transducer and activator of transcription (STAT) proteins are a family of transcription factors that have been shown to play an important role in tumor cell survival and proliferation.(7) STAT3, one of the STAT family members, is often constitutively active in human cancer cells, including MM, lymphoma, leukemi…”
BackgroundImaoka, H., Toiyama, Y., Saigusa, S., Kawamura, M., Kawamoto, A., Okugawa, Y., Hiro, J., Tanaka, K., Inoue, Y., Mohri, Y., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu327 · Cited by 111
“RacGAP1 accompanied by GTP-bound Rac1 works both as a mediator of tyrosine phosphorylation of the signal transducer and activator of transcription (STAT) family of proteins and as a nuclear localization signal-containing nuclear chaperone of phosphorylated STATs, which have a variety of functions including anti-apopto…”
BackgroundUlane, C. M., Kentsis, A., Cruz, C. D., Parisien, J.-P., Schneider, K. L., & Horvath, C. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10180-10189.2005 · Cited by 107
“Moreover, as inappropriately activated STAT protein pathways are known effectors of numerous human diseases including cancer and inflammation, understanding how V proteins specifically remove STATs from cells will identify opportunities for therapeutic intervention and may aid the development of novel STAT-directed th…”
BackgroundPrakobwong, S., Khoontawad, J., Yongvanit, P., Pairojkul, C., Hiraku, Y., Sithithaworn, P., Pinlaor, P., Aggarwal, B. B., & Pinlaor, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25656 · Cited by 106
Measles and rubella elimination in the WHO Region for Europe: progress and challenges
O'Connor, P., Jankovic, D., Muscat, M., Ben-Mamou, M., Reef, S., Papania, M., Singh, S., Kaloumenos, T., Butler, R., & Datta, S. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.01.003 · Cited by 107
Plasmablastic lymphoma: current perspectives
López, A., & Abrisqueta, P. (2018) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s142814 · Cited by 105
“The MYC gene has been considered untargetable because of a lack of binding domain.(63) Recently, a small selective molecule, bromodomain extraterminal (BET) inhibitor (JQ1) has shown to induce cell cycle arrest by inhibition of MYC transcription.”
BackgroundTargeting STAT3 in cancer and autoimmune diseases
Gharibi, T., Babaloo, Z., Hosseini, A., Abdollahpour‐Alitappeh, M., Hashemi, V., Marofi, F., Nejati‐Koshki, K., & Baradaran, B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173107 · Cited by 106
Signal transducer and activator of transcription 3 inhibitors: a patent review
Page, B. D., Ball, D. P., & Gunning, P. T. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.539205 · Cited by 102
“In normal cells, STAT activity is transiently activated and inhibited by a number of deactivation mechanisms, including SOCS proteinmediated silencing [13,14], association with protein inhibitors of activated STATs [15], dephosphorylation by nuclear phosphatases [14,16-18] and proteasomal degradation [19,20].”
Inflammasomes in Inflammation-Induced Cancer
Lin, C., & Zhang, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00271 · Cited by 118
Li, J., Yang, X., Sun, H., Xu, Y., Zhou, J., Qiu, S., Ke, A., Cui, Y., Wang, Z., Wang, W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.004 · Cited by 101
Understanding the Role of ETS-Mediated Gene Regulation in Complex Biological Processes
Findlay, V. J., LaRue, A. C., Turner, D. P., Watson, P. M., & Watson, D. K. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00001-0 · Cited by 125
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors
Chen, J., Bai, L., Bernard, D., Nikolovska-Coleska, Z., Gomez, C., Zhang, J., Yi, H., & Wang, S. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100010j · Cited by 100
Turco, M. C., Romano, M. F., Petrella, A., Bisogni, R., Tassone, P., & Venuta, S. (2003) · Leukemia · doi:10.1038/sj.leu.2403171 · Cited by 101
Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling
Kushal, S., Lao, B. B., Henchey, L. K., Dubey, R., Mesallati, H., Traaseth, N. J., Olenyuk, B. Z., & Arora, P. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312473110 · Cited by 98
“The blockade of transcription factor interactions can be especially attractive in targeting cellular pathways that promote oncogenic transformation and typically involve a large number of signaling proteins that ultimately converge on a much smaller set of oncogenic transcription factors (2).”
BackgroundKawashima, T., Bao, Y. C., Nomura, Y., Moon, Y., Tonozuka, Y., Minoshima, Y., Hatori, T., Tsuchiya, A., Kiyono, M., Nosaka, T., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200604073 · Cited by 100
Helix Mimetics as Inhibitors of the Interaction of the Estrogen Receptor with Coactivator Peptides
Becerril, J., & Hamilton, A. D. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700657 · Cited by 103
Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer
Kang, M. H., Choi, H., Oshima, M., Cheong, J., Kim, S., Lee, J. H., Park, Y. S., Choi, H., Kweon, M., Pack, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04244-2 · Cited by 109
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.